AAPL345.16+1.17 (+0.34%) ▲|ABBV283.70-1.11 (-0.39%) ▼|ABT102.40+1.89 (+1.88%) ▲|ACN250.63+10.37 (+4.32%) ▲|ADBE270.41+15.35 (+6.02%) ▲|AMAT382.87-26.07 (-6.38%) ▼|AMD515.87-36.85 (-6.67%) ▼|AMGN448.50+10.16 (+2.32%) ▲|AMT181.12+3.48 (+1.96%) ▲|AMZN252.83-9.54 (-3.64%) ▼|AVGO325.60-12.21 (-3.61%) ▼|AXP323.72+0.11 (+0.03%) ▲|BA189.87-2.41 (-1.25%) ▼|BAC50.94+0.16 (+0.31%) ▲|BKNG162.10+3.72 (+2.35%) ▲|BLK1,141.03-8.57 (-0.75%) ▼|BMY62.79+1.67 (+2.73%) ▲|BNY144.18-1.67 (-1.15%) ▼|BRK-B548.48+9.49 (+1.76%) ▲|C122.15-1.71 (-1.38%) ▼|CAT705.10-35.12 (-4.74%) ▼|CL96.83+3.43 (+3.67%) ▲|CMCSA22.88+0.80 (+3.62%) ▲|COF204.44-2.23 (-1.08%) ▼|COP144.88-0.79 (-0.54%) ▼|COST1,009.82+11.51 (+1.15%) ▲|CRM249.25+7.47 (+3.09%) ▲|CSCO104.56-2.71 (-2.52%) ▼|CVS93.99+1.21 (+1.30%) ▲|CVX224.37-2.41 (-1.06%) ▼|DE638.30+1.76 (+0.28%) ▲|DHR232.42-1.45 (-0.62%) ▼|DIS113.00+1.17 (+1.05%) ▲|DUK123.57+2.90 (+2.40%) ▲|EMR158.15-4.96 (-3.04%) ▼|FDX301.75+3.52 (+1.18%) ▲|GD346.66+1.95 (+0.57%) ▲|GE291.48-4.40 (-1.49%) ▼|GEV829.29-96.63 (-10.44%) ▼|GILD155.79+2.22 (+1.45%) ▲|GM76.95+0.84 (+1.10%) ▲|GOOG323.64-7.31 (-2.21%) ▼|GOOGL327.55-7.21 (-2.15%) ▼|GS891.71-13.01 (-1.44%) ▼|HD324.76+10.62 (+3.38%) ▲|HON215.50+0.77 (+0.36%) ▲|IBM249.07-2.40 (-0.95%) ▼|INTC87.75-5.21 (-5.60%) ▼|INTU355.65+20.04 (+5.97%) ▲|ISRG439.80+11.68 (+2.73%) ▲|JNJ266.77+8.99 (+3.49%) ▲|JPM334.54-0.65 (-0.19%) ▼|KO94.65+1.97 (+2.13%) ▲|LIN509.18+8.61 (+1.72%) ▲|LLY1,313.27+42.52 (+3.35%) ▲|LMT582.25+30.74 (+5.57%) ▲|LOW203.69+7.13 (+3.62%) ▲|LRCX235.46-25.35 (-9.72%) ▼|MA631.93+9.31 (+1.49%) ▲|MCD250.60+4.35 (+1.77%) ▲|MDLZ64.33+1.59 (+2.53%) ▲|MDT95.78+2.75 (+2.96%) ▲|META654.00-43.52 (-6.24%) ▼|MMM174.01-0.73 (-0.42%) ▼|MO75.39+1.56 (+2.11%) ▲|MRK152.09+2.21 (+1.47%) ▲|MS183.81-3.20 (-1.71%) ▼|MSFT526.09-6.86 (-1.29%) ▼|MU870.16-43.52 (-4.76%) ▼|NEE80.74+2.46 (+3.14%) ▲|NFLX67.23+2.19 (+3.36%) ▲|NKE38.25+0.72 (+1.92%) ▲|NOW156.61+3.49 (+2.28%) ▲|NVDA213.86-8.12 (-3.66%) ▼|ORCL126.23-2.90 (-2.25%) ▼|PEP137.97+3.27 (+2.43%) ▲|PFE30.27+0.42 (+1.39%) ▲|PG166.03+9.19 (+5.86%) ▲|PLTR199.03-2.69 (-1.33%) ▼|PM200.96+3.50 (+1.77%) ▲|QCOM175.40-2.57 (-1.44%) ▼|RTX191.82+0.22 (+0.11%) ▲|SBUX101.53+2.45 (+2.47%) ▲|SCHW92.34+0.70 (+0.76%) ▲|SO92.79+2.40 (+2.66%) ▲|SPG210.17+4.62 (+2.25%) ▲|T22.53+0.62 (+2.81%) ▲|TMO683.47-10.55 (-1.52%) ▼|TMUS157.52+3.77 (+2.45%) ▲|TSLA381.59-4.89 (-1.26%) ▼|TXN282.10-2.56 (-0.90%) ▼|UBER68.58+0.96 (+1.41%) ▲|UNH425.88+8.88 (+2.13%) ▲|UNP295.77+7.90 (+2.74%) ▲|UPS101.25+1.68 (+1.69%) ▲|USB59.89+0.84 (+1.41%) ▲|V414.18+6.33 (+1.55%) ▲|VZ44.59+1.03 (+2.36%) ▲|WFC83.08+0.66 (+0.80%) ▲|WMT120.13+2.33 (+1.98%) ▲|XOM176.13-1.97 (-1.10%) ▼|AAPL345.16+1.17 (+0.34%) ▲|ABBV283.70-1.11 (-0.39%) ▼|ABT102.40+1.89 (+1.88%) ▲|ACN250.63+10.37 (+4.32%) ▲|ADBE270.41+15.35 (+6.02%) ▲|AMAT382.87-26.07 (-6.38%) ▼|AMD515.87-36.85 (-6.67%) ▼|AMGN448.50+10.16 (+2.32%) ▲|AMT181.12+3.48 (+1.96%) ▲|AMZN252.83-9.54 (-3.64%) ▼|AVGO325.60-12.21 (-3.61%) ▼|AXP323.72+0.11 (+0.03%) ▲|BA189.87-2.41 (-1.25%) ▼|BAC50.94+0.16 (+0.31%) ▲|BKNG162.10+3.72 (+2.35%) ▲|BLK1,141.03-8.57 (-0.75%) ▼|BMY62.79+1.67 (+2.73%) ▲|BNY144.18-1.67 (-1.15%) ▼|BRK-B548.48+9.49 (+1.76%) ▲|C122.15-1.71 (-1.38%) ▼|CAT705.10-35.12 (-4.74%) ▼|CL96.83+3.43 (+3.67%) ▲|CMCSA22.88+0.80 (+3.62%) ▲|COF204.44-2.23 (-1.08%) ▼|COP144.88-0.79 (-0.54%) ▼|COST1,009.82+11.51 (+1.15%) ▲|CRM249.25+7.47 (+3.09%) ▲|CSCO104.56-2.71 (-2.52%) ▼|CVS93.99+1.21 (+1.30%) ▲|CVX224.37-2.41 (-1.06%) ▼|DE638.30+1.76 (+0.28%) ▲|DHR232.42-1.45 (-0.62%) ▼|DIS113.00+1.17 (+1.05%) ▲|DUK123.57+2.90 (+2.40%) ▲|EMR158.15-4.96 (-3.04%) ▼|FDX301.75+3.52 (+1.18%) ▲|GD346.66+1.95 (+0.57%) ▲|GE291.48-4.40 (-1.49%) ▼|GEV829.29-96.63 (-10.44%) ▼|GILD155.79+2.22 (+1.45%) ▲|GM76.95+0.84 (+1.10%) ▲|GOOG323.64-7.31 (-2.21%) ▼|GOOGL327.55-7.21 (-2.15%) ▼|GS891.71-13.01 (-1.44%) ▼|HD324.76+10.62 (+3.38%) ▲|HON215.50+0.77 (+0.36%) ▲|IBM249.07-2.40 (-0.95%) ▼|INTC87.75-5.21 (-5.60%) ▼|INTU355.65+20.04 (+5.97%) ▲|ISRG439.80+11.68 (+2.73%) ▲|JNJ266.77+8.99 (+3.49%) ▲|JPM334.54-0.65 (-0.19%) ▼|KO94.65+1.97 (+2.13%) ▲|LIN509.18+8.61 (+1.72%) ▲|LLY1,313.27+42.52 (+3.35%) ▲|LMT582.25+30.74 (+5.57%) ▲|LOW203.69+7.13 (+3.62%) ▲|LRCX235.46-25.35 (-9.72%) ▼|MA631.93+9.31 (+1.49%) ▲|MCD250.60+4.35 (+1.77%) ▲|MDLZ64.33+1.59 (+2.53%) ▲|MDT95.78+2.75 (+2.96%) ▲|META654.00-43.52 (-6.24%) ▼|MMM174.01-0.73 (-0.42%) ▼|MO75.39+1.56 (+2.11%) ▲|MRK152.09+2.21 (+1.47%) ▲|MS183.81-3.20 (-1.71%) ▼|MSFT526.09-6.86 (-1.29%) ▼|MU870.16-43.52 (-4.76%) ▼|NEE80.74+2.46 (+3.14%) ▲|NFLX67.23+2.19 (+3.36%) ▲|NKE38.25+0.72 (+1.92%) ▲|NOW156.61+3.49 (+2.28%) ▲|NVDA213.86-8.12 (-3.66%) ▼|ORCL126.23-2.90 (-2.25%) ▼|PEP137.97+3.27 (+2.43%) ▲|PFE30.27+0.42 (+1.39%) ▲|PG166.03+9.19 (+5.86%) ▲|PLTR199.03-2.69 (-1.33%) ▼|PM200.96+3.50 (+1.77%) ▲|QCOM175.40-2.57 (-1.44%) ▼|RTX191.82+0.22 (+0.11%) ▲|SBUX101.53+2.45 (+2.47%) ▲|SCHW92.34+0.70 (+0.76%) ▲|SO92.79+2.40 (+2.66%) ▲|SPG210.17+4.62 (+2.25%) ▲|T22.53+0.62 (+2.81%) ▲|TMO683.47-10.55 (-1.52%) ▼|TMUS157.52+3.77 (+2.45%) ▲|TSLA381.59-4.89 (-1.26%) ▼|TXN282.10-2.56 (-0.90%) ▼|UBER68.58+0.96 (+1.41%) ▲|UNH425.88+8.88 (+2.13%) ▲|UNP295.77+7.90 (+2.74%) ▲|UPS101.25+1.68 (+1.69%) ▲|USB59.89+0.84 (+1.41%) ▲|V414.18+6.33 (+1.55%) ▲|VZ44.59+1.03 (+2.36%) ▲|WFC83.08+0.66 (+0.80%) ▲|WMT120.13+2.33 (+1.98%) ▲|XOM176.13-1.97 (-1.10%) ▼|
16.1 C
New York
Thursday, October 22, 2026

Tag: presentations

Alpha-synuclein Inhibitors Market to Witness Strong CAGR Through 2034, Driven by Advances in Neurodegenerative Therapies | DelveInsight

No alpha-synuclein inhibitors are approved, underscoring a major need for therapies that slow or halt Parkinson's progression. Developing safe, brain-penetrant drugs that target toxic...

GBank Financial Holdings Inc. Announces Second Quarter 2025 Financial Results

GBank Financial Holdings Inc. Announces Second Quarter 2025 Financial Results

In Celebration of Tony Bennett’s Birthday, CARNEGIE HALL+ Announces the Streaming Premiere of BECAUSE OF YOU, Michael Feinstein’s Concert Tribute to Tony Bennett, Beginning...

Special streaming premiere of performance featuring the Carnegie Hall Big Band, filmed on tour at Segerstrom Center for the Arts, available for the first...

Fluence Energy, Inc. Announces Third Quarter 2025 Earnings Release Date, Conference Call and Webcast

ARLINGTON, Va., July 28, 2025 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. (Nasdaq: FLNC) (“Fluence” or the “Company”), announced today that it will report earnings for the third quarter ended June 30th, 2025 on Monday, August 11th, 2025, after market close.

PTC Therapeutics Announces FDA Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)

- Broad labeling inclusive of all disease subtypes for individuals 1 month of age and older - - PTC will host a conference call on...

Simpson Manufacturing Co., Inc. Announces 2025 Second Quarter Financial Results and Reaffirms 2025 Guidance

Net sales of $631.1 million increased 5.7% year-over-yearIncome from operations of $140.2 million increased 6.1% year-over-yearNet income per diluted share of $2.47 increased 6.9%...

Whirlpool Corporation Announces Second-Quarter Results

Delivered sequential net sales growth across all segments, despite negative consumer sentiment impacting global demandDelivered significant cost take out of 100 basis points or...

Alamar Biosciences Showcases Pioneering Brain-Derived pTau Data at the Alzheimer’s Association International Conference (AAIC)

Groundbreaking Insights into Neurodegenerative Disease Biomarkers to be Unveiled through 30+ Posters and Presentations at International Meeting FREMONT, Calif., July 28, 2025 /PRNewswire/ -- Alamar...

Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

CELEBRATION, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare diseases, announced the company submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the evaluation of arimoclomol for the treatment of Niemann-Pick Disease Type C (NPC). NPC is an ultra-rare, neurological disease caused by genetic mutations that result in lipid accumulation in cells, leading to visceral, neurological, and psychiatric symptoms. Arimoclomol is the only treatment shown to directly target the underlying pathology of NPC by increasing gene expression for improved lipid clearance. Arimoclomol for the treatment of NPC has been designated as an Orphan Medicinal Product by the EMA. Arimoclomol is marketed in the U.S. under the brand name MIPLYFFA®.

Notice of Results

Release of Second Quarter 2025 Results

Roche presents new insights in Alzheimer’s disease research across its diagnostics and pharmaceutical portfolios at AAIC

Basel, 28 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer’s development portfolio is being presented at the Alzheimer’s Association International Conference (AAIC) in Toronto, Canada (July 27-30). These data exemplify the comprehensive approach Roche is taking in addressing Alzheimer’s across the entire patient journey. 

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop

– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel long-acting herpes simplex virus helicase-primase inhibitor candidates –

Gentex Reports Second Quarter 2025 Financial Results

ZEELAND, Mich., July 25, 2025 (GLOBE NEWSWIRE) -- Gentex Corporation (NASDAQ: GNTX), a leading supplier of digital vision, connected car, dimmable glass, fire protection technologies, medical devices, and consumer electronics, today reported financial results for the three and six months ended June 30, 2025.

Portland General Electric Announces Second Quarter 2025 Results

Second quarter financial results reflect significant demand growth from data center customers, driving 16.5% industrial load growth quarter-over-quarterAdvancing recovery of the Seaside battery, distribution...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPresentations